Cancer Research

Oral SERD Elacestrant is now an option for metastatic hormone-receptor positive breast cancer: Findings from the Phase III EMERALD Trial

By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center   Endocrine therapy is the mainstay of the management of hormone…

2 years ago

Dr. Rubina Suwal of the Binaytara Foundation Cancer Center Receives ASCO International Innovation Grant

The International Innovation Grant will Fund Research on the Effectiveness of Community Screening Programs for the Early Detection of Oral…

2 years ago

Zuma 7 trial shows statistically significant overall survival benefit for yescarta

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter…

2 years ago

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG…

2 years ago

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung…

2 years ago

2022 Updates in Lung Cancer Treatment

By Dr. Kanak Parmar Texas Tech University   Perioperative systemic therapy for resectable non-small cell lung cancer Surgical resection followed…

2 years ago

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the…

2 years ago

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced…

2 years ago

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which…

2 years ago

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by…

2 years ago